CytomX Therapeutics (CTMX) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' Net Income towards Common Stockholders fell 34806.49% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 10258.86%. This contributed to the annual value of $31.9 million for FY2024, which is 570087.87% up from last year.
- Latest data reveals that CytomX Therapeutics reported Net Income towards Common Stockholders of -$14.2 million as of Q3 2025, which was down 34806.49% from -$154000.0 recorded in Q2 2025.
- CytomX Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $23.5 million during Q1 2025, with a 5-year trough of -$34.8 million in Q4 2021.
- Over the past 5 years, CytomX Therapeutics' median Net Income towards Common Stockholders value was -$6.5 million (recorded in 2024), while the average stood at -$9.2 million.
- Over the last 5 years, CytomX Therapeutics' Net Income towards Common Stockholders had its largest YoY gain of 215519.71% in 2024, and its largest YoY loss of 50110.4% in 2024.
- CytomX Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$34.8 million in 2021, then soared by 74.8% to -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then surged by 2155.2% to $18.9 million in 2024, then crashed by 175.38% to -$14.2 million in 2025.
- Its last three reported values are -$14.2 million in Q3 2025, -$154000.0 for Q2 2025, and $23.5 million during Q1 2025.